Press Releases

NS Pharma, Inc.a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. , today announced that the U.S. FDA has granted Orphan Drug Designation to NS-018 an investigational treatment for myelofibrosis  a rare and incurable blood cancer.The FDA issues Orphan Drug Designations to support the development and evaluation of new treatments to prevent, diagnose, or treat a rare disease or condition. MF is caused by buildup of excessive scar tissue in the bone marrow, which impairs the b

KKR, a leading global investment firm, and Bushu Pharmaceuticals Ltd. today announced the signing of definitive agreements under which KKR will acquire all shares in Bushu Pharma from BPEA EQT. Following the transaction’s completion, KKR aims to accelerate Bushu Pharma’s growth and further position the Company as a leading contract development and manufacturing organization (“CDMO”) for the pharmaceuticals market in Japan and worldwide. Founded in 1998, Bushu

ANI Pharmaceuticals, Inc. today announced that it received U.S. Food and Drug Administration approval for the Abbreviated New Drug Application for Levocarnitine Tablets USP, 330 mg.ANI’s Levocarnitine Tablets are the generic version of the Reference Listed Drug Carnitor. The current annual U.S. market for Levocarnitine Tablets is approximately $10.0 million, according to IQVIA/IMS Health, a leading healthcare data and analytics provider. "The launch of Levocarnitine Table

Biocytogen Pharmaceuticals Co., Ltd. announced today that the US FDA has approved the Investigational New Drug application for a phase I study of YH008, an internally developed first-in-class PD-1 x CD40 bispecific antibody. The IND application was completed by Eucure Biopharma, the wholly owned subsidiary of Biocytogen. The study is an open-label, dose-escalation study (No. YH008101) that will evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity o

Innate Pharma SA and Sanofi announced today an expansion of their collaboration, with Sanofi licensing a natural killer cell engager program targeting B7H3 from Innate’s ANKETTM  platform. Sanofi will also have the option to add up to two additional ANKETTM targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization. Innate and Sanofi signed a first NK cell engagers collaboration in 2016 for the generation and eva

China Pharma Holdings, Inc. an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its drugs were listed in The Catalogue of Medicines for People Infected with COVID-19 published by People's Daily on December 12, 2022.  Recently, China has completely ended its strict quarantine and zero case policies in response to COVID-19 pandemic in the past three years. Out of concern about the spread

WuXi STA, a subsidiary of WuXi AppTec, received the latest scores from EcoVadis rating, a trusted provider of business sustainability ratings, for active pharmaceutical ingredients (API) R&D and manufacturing from its Changzhou site, and for formulation development and manufacturing from its Shanghai Waigaoqiao site and Wuxi city site, respectively. All three China sites received scores of 60+ with a "Silver" rating from EcoVadis, powering the company to a leading position in th

Hovione and GEA today announced a strategic collaboration to advance Continuous Tableting. This partnership stemmed from a successful customer-supplier relationship spanning several years. It combines GEA´s engineering expertise with Hovione´s development and manufacturing experience and both parties commit to partner to accelerate the adoption of Continuous Tableting technology.The advantages of continuous over batch manufacturing are well known. Continuous production systems all

Clinithink, the company that has developed the world’s first Healthcare AI capable of truly understanding unstructured medical notes, has partnered with AstraZeneca Oncology UK in a new project that aims to find patients with lung cancer at an early stage where treatment can be more effective. The project announced today hopes to demonstrate potential savings based on this novel AI approach as well as identify benefits for patients in being treated earlier in the disease proce

JB Pharma, one of the fastest growing pharmaceutical companies in India, has entered into an agreement with Glenmark Pharmaceuticals Ltd., to acquire the entire Razel (Rosuvastatin) franchise for the India and Nepal region for a whopping Rs. 313.7 crores. With this acquisition, JB Pharma will complete its cardiac portfolio making it a leader in this segment, as Razel ranks among the top 10 brands in the Rosuvastatin molecule category in the country. These brands are focused on cardiac se